IPP-1 ELO

IPP-1 ELO — Selective Amylin Receptor Agonist Research Peptide

IPP-1 ELO is a synthetic, fatty-acid–acylated analog of human amylin. Unlike earlier amylin analogs that activate amylin and calcitonin receptors non-selectively, IPP-1 ELO was engineered to preferentially activate the AMY1R amylin-receptor subtype, making it a distinctive tool for researchers studying receptor-selective amylin biology. IPP-1 ELO remains an investigational research compound. Iron Peak Peptides supplies IPP-1 ELO strictly as a research-use-only (RUO) reagent for in-vitro and laboratory investigation — it is not for human or animal consumption, self-administration, diagnostic use, or therapeutic use of any kind, and nothing on this page constitutes medical advice. Each vial contains lyophilized peptide verified for purity by HPLC and mass spectrometry.

What Is IPP-1 ELO?

IPP-1 ELO is an experimental research peptide belonging to the amylin receptor agonist class, the same broad pharmacological family as pramlintide and cagrilintide. It was designed with amino-acid substitutions and a fatty-acid acylation strategy intended to extend plasma half-life while shifting receptor engagement toward a single amylin receptor subtype. In published translational research, this selectivity profile has been proposed as a mechanistic basis for differentiating IPP-1 ELO from non-selective amylin analogs. Researchers investigating amylin/calcitonin receptor pharmacology, RAMP biology, or satiety-signaling pathways may find IPP-1 ELO useful as a subtype-selective pharmacological tool alongside non-selective comparators such as cagrilintide.

Amylin Receptor Selectivity & Mechanism of Action

Amylin Receptor Biology

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic β-cells in response to nutrient intake. Amylin signals through a family of receptor complexes formed when the calcitonin receptor (CTR) heterodimerizes with one of three receptor-activity-modifying proteins (RAMP1, RAMP2, or RAMP3), generating the AMY1R, AMY2R, and AMY3R subtypes, respectively. These receptors are expressed in the area postrema and other hindbrain nuclei implicated in vagally mediated satiety and gastric-emptying signaling. Native calcitonin binds CTR itself with the highest affinity, while amylin preferentially engages the RAMP-associated amylin receptor subtypes; this differential affinity is the basis researchers use to classify amylin receptor agonists as selective or non-selective.

AMY1R-Selective Agonism

In vitro receptor pharmacology published by Briere and colleagues characterized IPP-1 ELO's activity across cell lines individually expressing human AMY1R, AMY3R, or CTR. The investigators reported that IPP-1 ELO activated human AMY1R with approximately 12-fold greater potency than human CTR and approximately 11-fold greater potency than human AMY3R in cAMP-accumulation assays, while achieving full agonism (Emax >80%) at all three receptors. Radioligand binding assays reported a parallel selectivity pattern, with roughly 8-fold higher binding affinity for AMY1R relative to both CTR and AMY3R. In rodent receptor assays, the selectivity margin over CTR was even larger, with investigators reporting up to a 109-fold difference in binding affinity for rat AMY1R versus rat CTR. This contrasts mechanistically with cagrilintide, which published pharmacology characterizes as a non-selective amylin/calcitonin receptor agonist with comparable activity across AMY1R, AMY3R, and CTR.

Acylation & Pharmacokinetic Profile

IPP-1 ELO's C20 fatty-diacid conjugate promotes reversible binding to circulating albumin, a modification researchers use broadly across peptide therapeutics to slow renal clearance and proteolytic degradation. In head-to-head pharmacokinetic studies in rats and cynomolgus monkeys, investigators reported that IPP-1 ELO achieved higher systemic exposure, a longer terminal half-life, and a flatter plasma concentration-time profile than cagrilintide at matched molar doses — PK characteristics researchers have linked to its once-weekly dosing design in the clinical studies described below.

IPP-1 ELO vs. Cagrilintide vs. GLP-1–Based Compounds

The table below summarizes receptor pharmacology across several metabolic research peptides commonly studied together in incretin and amylin biology research. It reflects receptor-binding classifications reported in the primary literature, not comparative efficacy claims.

Published Research

Preclinical Pharmacology

Published translational research has characterized IPP-1 ELO's receptor pharmacology, pharmacokinetics, and preclinical efficacy in rodent models. In lean-rat conditioned taste avoidance assays — a rodent model researchers use as a proxy for nausea-like malaise — investigators reported significantly less taste aversion with IPP-1 ELO than cagrilintide despite comparable reductions in food intake between the two peptides. In diet-induced obese rat models, repeated dosing with IPP-1 ELO reduced food intake and body weight predominantly through loss of fat mass, with reported preservation of lean mass to a significantly greater degree than cagrilintide at matched doses. Combination studies in diet-induced obese rat models have also reported that pairing IPP-1 ELO with IPP-2 TRZ enhanced weight-loss efficacy relative to either compound alone, informing ongoing combination-mechanism research.

Early-Phase Clinical Research

Published early-phase clinical research has evaluated IPP-1 ELO in randomized, placebo-controlled, dose-escalation study designs in healthy adult volunteers. IPP-1 ELO was generally well tolerated across the dose ranges studied, with the large majority of treatment-emergent adverse events assessed as mild; gastrointestinal events such as nausea and vomiting were reported infrequently and predominantly at the highest doses evaluated. Pharmacokinetic analyses reported dose-proportional exposure and a terminal half-life consistent with once-weekly dosing, along with dose-dependent reductions in body weight relative to placebo. A separate multiple-ascending-dose study design evaluated once-weekly IPP-1 ELO dosing without dose escalation in adult study participants, reporting good tolerability and dose-dependent reductions in body weight relative to placebo.

Later-Phase Clinical Research

A published multicentre, double-blind, randomised, placebo-controlled clinical trial evaluated several once-weekly IPP-1 ELO dosing regimens against placebo in adult study participants over a 48-week period. IPP-1 ELO met its primary endpoint, achieving a statistically significant reduction in body weight relative to placebo across all arms, with the reported effect increasing at higher exposure levels; secondary analyses reported improvements in BMI and several cardiometabolic risk markers. The most frequent adverse events were gastrointestinal symptoms and fatigue, occurring more at higher exposure levels, with tolerability at the lowest levels studied described as comparable to placebo. Additional published and ongoing research has separately evaluated IPP-1 ELO alone and in combination with IPP-2 TRZ in adult study cohorts. Later-phase clinical research in this compound class is understood to be ongoing, with no topline results publicly reported at the time of this writing.

Preclinical & Research Model Applications

Receptor Pharmacology & RAMP Biology

Because IPP-1 ELO's receptor engagement is skewed toward AMY1R relative to AMY3R and CTR, it is used in receptor pharmacology research as a comparator tool for dissecting the individual contributions of RAMP1-, RAMP2-, and RAMP3-associated amylin receptor complexes in cell-based and tissue-based assays.

Satiety & Energy-Balance Signaling

Rodent studies cited above used IPP-1 ELO to probe hindbrain and area-postrema-mediated satiety circuits, food-intake regulation, and body-composition changes in lean and diet-induced obese models, providing a selective pharmacological probe distinct from non-selective amylin analogs.

Combination Incretin Research

Preclinical and clinical research programs have paired IPP-1 ELO with the dual incretin agonist IPP-2 TRZ to characterize combined effects on energy balance in animal models and in an ongoing clinical study, offering researchers a reference point for combination mechanistic research alongside other incretin-pathway compounds such as IPP-3 RT and IPP-1 SM.

Analytical Characterization

Reputable suppliers of synthetic research peptides characterize each lot using orthogonal analytical methods rather than a single purity figure. Reverse-phase HPLC (RP-HPLC) resolves the target peptide from truncation and deletion sequence variants and is the primary method used to report percent purity. Electrospray ionization mass spectrometry (ESI-MS) or LC-MS confirms the intact molecular mass and detects mass-shifted degradation species such as deamidated or oxidized variants. Because RP-HPLC purity reflects the proportion of peptide-related substances rather than total vial content, gross mass and net peptide content (accounting for residual counter-ions, water, and synthesis-related solvents) are reported separately on lot-specific documentation. Chiral purity checks confirm retention of the all-L-amino-acid configuration reported for IPP-1 ELO's backbone, since epimerization during synthesis can generate diastereomeric impurities that co-elute poorly on standard gradients.

Reconstitution and Handling in Research

The following summarizes standard laboratory handling for lyophilized research peptides. This product is intended for research use only and is not for human consumption.

Reconstitute the lyophilized powder by adding bacteriostatic or sterile water down the inside wall of the vial using a sterile syringe, then gently swirl to dissolve — do not shake, as vigorous agitation can shear peptide structure. The acylated fatty-acid moiety on IPP-1 ELO's backbone increases its tendency to adsorb to glass and plastic surfaces relative to non-lipidated peptides, so investigators should account for potential losses when preparing dilute working solutions. For general technique and dilution calculations, see our peptide reconstitution guide and pair with bacteriostatic water.

Storage and Handling

Lyophilized (unreconstituted): Store at -20°C for long-term stability or at 2–8°C for shorter periods, protected from light and moisture. Avoid repeated freeze-thaw cycles.

Reconstituted: Store at 2–8°C and use within a few weeks; for longer storage, aliquot and freeze at -20°C. As with many peptide reagents, deamidation, oxidation of susceptible side chains, and slow hydrolysis of the acylated side chain are the principal degradation pathways researchers guard against via buffer pH and storage temperature. See our full peptide storage guide.

Purity & Quality Assurance

Each batch of IPP-1 ELO is analyzed for purity and identity using RP-HPLC and mass spectrometry prior to release, with lot-specific documentation available for research recordkeeping. Because IPP-1 ELO is a newly characterized research compound without a long history of third-party reference standards, investigators are encouraged to independently verify identity and purity on receipt using their own analytical methods where rigorous confirmation is required for a given research protocol. This is an honest limitation common to any newly available synthetic peptide and is not unique to this product.

Safety Profile in Research

As with all research compounds, investigators should follow standard laboratory safety protocols, including appropriate personal protective equipment (PPE) when handling reconstituted solutions. IPP-1 ELO is an investigational research compound. It is not intended for human consumption, therapeutic use, self-administration, or diagnostic purposes, and it is not a substitute for any medication. It is sold by Iron Peak Peptides exclusively for in-vitro and laboratory research use, and nothing in this description constitutes medical advice or a recommendation for use in humans or animals outside of a properly conducted research protocol.

Related Research Compounds

Researchers studying IPP-1 ELO often study it alongside other metabolic research peptides available from Iron Peak Peptides:

• Cagrilintide 10mg — a non-selective, long-acting amylin/calcitonin receptor agonist and the closest mechanistic comparator to IPP-1 ELO.
• IPP-1 SM 10mg — a GLP-1 receptor agonist frequently studied in combination-incretin research.
• IPP-2 TRZ 10mg — a dual GIP/GLP-1 receptor agonist studied in combination with amylin receptor agonists in preclinical models.
• IPP-3 RT 10mg — a triple glucagon/GIP/GLP-1 receptor agonist used as a reference compound in broader incretin-pathway research.

Frequently Asked Questions

What is IPP-1 ELO?

IPP-1 ELO is a synthetic, fatty-acid–acylated amylin analog engineered as a selective amylin receptor agonist, supplied here strictly as a research-use-only reagent for laboratory investigation.

Is IPP-1 ELO the same as cagrilintide?

No. Both are amylin analogs, but published pharmacology describes cagrilintide as non-selective across amylin and calcitonin receptor subtypes, whereas IPP-1 ELO preferentially activates AMY1R over CTR and AMY3R in vitro.

How does IPP-1 ELO differ from GLP-1 receptor agonists?

IPP-1 ELO acts on amylin receptor complexes (CTR combined with RAMP1), a mechanistically distinct target from the GLP-1 receptor engaged by IPP-1 SM, or the dual/triple incretin receptor agonists IPP-2 TRZ and IPP-3 RT.

What does "AMY1R-selective" mean?

It refers to a receptor pharmacology profile in which a compound preferentially activates the AMY1R amylin-receptor subtype relative to AMY3R and the calcitonin receptor, rather than activating all three with comparable potency.

What research model systems is IPP-1 ELO studied in?

Published research on IPP-1 ELO spans in vitro receptor-binding and cAMP-signaling assays, lean and diet-induced obese rodent models, and early-phase human clinical research. It is intended strictly for laboratory research use.

What is the purity of IPP-1 ELO?

Each batch is verified at ≥99% purity by HPLC and mass spectrometry, with lot-specific analytical documentation available for research recordkeeping.

What research has been published on IPP-1 ELO?

Published research includes preclinical receptor-pharmacology and rodent efficacy studies, phase 1 single- and multiple-ascending-dose trials, and a phase 2 randomized controlled trial, cited below. Phase 3 studies are ongoing and have not yet reported results.

Can IPP-1 ELO be used with GLP-1 research compounds?

Published and ongoing research has evaluated IPP-1 ELO alongside the dual incretin agonist IPP-2 TRZ in animal models and an ongoing clinical study, making it relevant to combination-mechanism research alongside GLP-1 and multi-agonist incretin compounds.

What vial sizes does Iron Peak Peptides offer?

IPP-1 ELO is offered in 5 mg and 10 mg lyophilized vials; availability of each size may vary. Please refer to the product options above for current availability.

Is IPP-1 ELO safe for human use?

IPP-1 ELO sold by Iron Peak Peptides is not intended for human use. It is an unapproved, investigational compound supplied strictly for laboratory research, and safety findings referenced here describe outcomes reported within registered clinical trials, not general use.

Why Buy IPP-1 ELO from Iron Peak Peptides?

Every batch of IPP-1 ELO undergoes analytical testing — RP-HPLC and mass spectrometry — to verify purity, identity, and composition, with batch-specific quality-assurance documentation available on request. Iron Peak Peptides maintains full traceability from raw material to finished vial, ships quickly with proper handling, and backs every order with responsive research support. As a newly available research compound, we are committed to updating this page as additional peer-reviewed literature on IPP-1 ELO becomes available.

References & Research Resources

IPP-1 ELO belongs to the amylin-receptor agonist research class alongside compounds such as cagrilintide. For general background on amylin receptor pharmacology and receptor-selective agonist research, see the following resources:

1. PubChem: Amylin (Islet Amyloid Polypeptide) Compound Summary.
2. Browse current amylin-receptor agonist and AMY1R-selectivity primary literature on PubMed.
3. — batch-specific analytical documentation for IPP-1 ELO.

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. IPP-1 ELO is an investigational research compound. The IPP-1 ELO sold here is supplied exclusively as a research compound, is not intended for human or animal consumption, self-administration, or diagnostic use, and is not a substitute for any medication. All information above is derived from general, publicly available scientific background on the amylin-receptor agonist research class. Research must comply with all applicable laws, regulations, and institutional guidelines.